Aegis Awarded Its First Patent for Oral Delivery of Nucleotide-Based Drugs With High Bioavailability

SAN DIEGO, CA--(Marketwired - Feb 5, 2014) - Aegis Therapeutics LLC announced today that it has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon Aegis' patented Intravail® transmucosal absorption enhancer technology. U.S. Patent No. 8,642,564 provides methods for oral delivery of nucleotide-oligomer analogs including anti-sense and RNA interference drugs. Such drugs represent an important new class of therapeutics but are generally poorly absorbed in the GI tract and thus must be administered by injection. Oral delivery provides greater patient convenience and acceptance as well as reduced administration costs and greater flexibility in dosing schedules to allow for maximum therapeutic efficacy.
Aegis licenses its Intravail® drug delivery and ProTek® protein stabilization technologies to biopharmaceutical companies worldwide.
To receive future press releases directly via email click here and enter your email address in the sign-up box at the bottom of the page.
About Aegis Therapeutics
Aegis Therapeutics LLC commercializes its patented drug formulation technologies through product-specific licenses. Intravail® drug delivery technology enables non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding oxidative damage caused by polysorbate surfactants.
For more information about Aegis, please visit: